|
US20030143647A1
(en)
|
2001-09-24 |
2003-07-31 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Anticancer vaccine and diagnostic methods and reagents
|
|
WO2005113595A2
(en)
*
|
2004-05-19 |
2005-12-01 |
Avidex Ltd |
High affinity ny-eso t cell receptor
|
|
CA2572964C
(en)
|
2004-07-06 |
2018-03-06 |
3D Matrix, Inc. |
Purified amphiphilic peptide compositions and uses thereof
|
|
WO2006036445A2
(en)
|
2004-09-24 |
2006-04-06 |
Trustees Of Dartmouth College |
Chimeric nk receptor and methods for treating cancer
|
|
WO2007044033A2
(en)
*
|
2004-12-07 |
2007-04-19 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
|
|
ATE423140T1
(de)
|
2005-01-05 |
2009-03-15 |
F Star Biotech Forsch & Entw |
Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
|
|
GB0511124D0
(en)
*
|
2005-06-01 |
2005-07-06 |
Avidex Ltd |
High affinity melan-a t cell receptors
|
|
US8883507B2
(en)
|
2005-10-18 |
2014-11-11 |
The Regents Of The University Of Colorado |
Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells
|
|
US20090208502A1
(en)
*
|
2005-12-20 |
2009-08-20 |
Ralph Alexander Willemsen |
Apoptosis-inducing protein complexes and therapeutic use thereof
|
|
AT503861B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von t-zell-rezeptoren
|
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
|
WO2008039818A2
(en)
*
|
2006-09-26 |
2008-04-03 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Modified t cell receptors and related materials and methods
|
|
WO2008037943A1
(en)
*
|
2006-09-29 |
2008-04-03 |
Medigene Limited |
Cells transformed with nucleic acid encoding ny-eso t cell receptors
|
|
EP2087000A2
(en)
*
|
2006-09-29 |
2009-08-12 |
Immunocore Ltd. |
T cell therapies
|
|
PL3241842T3
(pl)
|
2007-06-26 |
2024-06-10 |
F-Star Therapeutics Limited |
Prezentacja środków wiążących
|
|
CA2700278A1
(en)
*
|
2007-09-25 |
2009-04-02 |
The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services |
Modified t cell receptors and related materials and methods
|
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
|
SG10201803982TA
(en)
|
2008-05-16 |
2018-07-30 |
Taiga Biotechnologies Inc |
Antibodies and processes for preparing the same
|
|
WO2010011994A2
(en)
|
2008-07-25 |
2010-01-28 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Polypeptides and uses thereof
|
|
US8784825B2
(en)
|
2008-08-28 |
2014-07-22 |
Taiga Biotechnologies, Inc. |
Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
|
|
GB0816096D0
(en)
*
|
2008-09-04 |
2008-10-15 |
Medigene Ltd |
Diabetes t cell receptors
|
|
GB0908613D0
(en)
|
2009-05-20 |
2009-06-24 |
Immunocore Ltd |
T Cell Reseptors
|
|
US9273283B2
(en)
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
|
US12492376B2
(en)
|
2009-10-29 |
2025-12-09 |
The Trustees Of Dartmouth College |
T-cell receptor-deficient T cell compositions
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
JP2013535199A
(ja)
*
|
2010-07-28 |
2013-09-12 |
イムノコア リミテッド |
T細胞レセプター
|
|
US9833476B2
(en)
|
2011-08-31 |
2017-12-05 |
The Trustees Of Dartmouth College |
NKP30 receptor targeted therapeutics
|
|
WO2013041865A1
(en)
*
|
2011-09-22 |
2013-03-28 |
Immunocore Limited |
T cell receptors
|
|
WO2013048243A1
(en)
|
2011-09-29 |
2013-04-04 |
Apo-T B.V. |
Multi-specific binding molecules targeting aberrant cells
|
|
EP2802356A1
(en)
|
2012-01-13 |
2014-11-19 |
Apo-T B.V. |
Aberrant cell-restricted immunoglobulins provided with a toxic moiety
|
|
CN104395344B
(zh)
|
2012-05-07 |
2019-08-13 |
达特茅斯大学理事会 |
抗b7-h6抗体、融合蛋白及其使用方法
|
|
ES2835200T3
(es)
|
2012-05-22 |
2021-06-22 |
Us Health |
Uso médico de células que comprenden receptores de células T anti-NY-ESO-1
|
|
JP6285930B2
(ja)
|
2012-07-20 |
2018-02-28 |
タイガ バイオテクノロジーズ,インク. |
造血コンパートメントの再構築及び自家再構築の増進
|
|
NZ741124A
(en)
|
2012-07-27 |
2019-11-29 |
Univ Illinois |
Engineering t-cell receptors
|
|
US10272115B2
(en)
|
2013-03-11 |
2019-04-30 |
Taiga Biotechnologies, Inc. |
Production and use of red blood cells
|
|
DK2971045T3
(da)
|
2013-03-13 |
2019-09-16 |
Health Research Inc |
Sammensætninger og fremgangsmåder til anvendelse af rekombinante T-celle-receptorer til direkte genkendelse af tumorantigen
|
|
AU2014235968B2
(en)
|
2013-03-21 |
2018-05-24 |
Ospedale San Raffaele Srl |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
JP6549564B2
(ja)
|
2013-06-26 |
2019-07-24 |
グアンドン シャンスエ ライフ サイエンス, リミテッド. |
高安定性のt細胞受容体およびその製法と使用
|
|
JP6476182B2
(ja)
|
2013-11-22 |
2019-02-27 |
ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ |
改変された高親和性ヒトt細胞受容体
|
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
|
JP7060324B2
(ja)
|
2013-12-20 |
2022-04-26 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
ネオ抗原ワクチンによる併用療法
|
|
ES2740930T3
(es)
*
|
2014-03-14 |
2020-02-07 |
Immunocore Ltd |
Bibliotecas de TCR
|
|
WO2016014725A1
(en)
|
2014-07-22 |
2016-01-28 |
The University Of Notre Dame Du Lac |
Molecular constructs and uses thereof
|
|
US10201597B2
(en)
|
2014-09-30 |
2019-02-12 |
The Regents Of The University Of California |
Codon-optimized lentiviral vector for stem cell reprogramming
|
|
KR102546296B1
(ko)
|
2014-10-31 |
2023-06-21 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
|
|
US10975442B2
(en)
|
2014-12-19 |
2021-04-13 |
Massachusetts Institute Of Technology |
Molecular biomarkers for cancer immunotherapy
|
|
EP3234130B1
(en)
|
2014-12-19 |
2020-11-25 |
The Broad Institute, Inc. |
Methods for profiling the t-cell- receptor repertoire
|
|
GB201506642D0
(en)
*
|
2015-04-20 |
2015-06-03 |
Ucl Business Plc |
T cell receptor
|
|
CN106279404A
(zh)
*
|
2015-05-20 |
2017-01-04 |
广州市香雪制药股份有限公司 |
一种可溶且稳定的异质二聚tcr
|
|
JP6913032B2
(ja)
|
2015-05-20 |
2021-08-04 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
共通ネオ抗原
|
|
NL2014935B1
(en)
|
2015-06-08 |
2017-02-03 |
Applied Immune Tech Ltd |
T cell receptor like antibodies having fine specificity.
|
|
AU2016279062A1
(en)
|
2015-06-18 |
2019-03-28 |
Omar O. Abudayyeh |
Novel CRISPR enzymes and systems
|
|
EP4339287A3
(en)
|
2015-07-31 |
2024-05-22 |
Regents Of The University Of Minnesota |
Modified cells and methods of therapy
|
|
GB201516272D0
(en)
*
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
|
US12241053B2
(en)
|
2015-10-09 |
2025-03-04 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
|
CA3005878A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
|
GB201522592D0
(en)
*
|
2015-12-22 |
2016-02-03 |
Immunocore Ltd |
T cell receptors
|
|
GB201604953D0
(en)
|
2016-03-23 |
2016-05-04 |
Immunocore Ltd |
T cell receptors
|
|
EP4166161B1
(en)
|
2016-04-14 |
2026-03-04 |
Fred Hutchinson Cancer Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
|
AU2017254477A1
(en)
|
2016-04-18 |
2018-11-01 |
Jennifer G. ABELIN |
Improved HLA epitope prediction
|
|
JP7599819B2
(ja)
|
2016-06-02 |
2024-12-16 |
イムノコア リミテッド |
gp100特異的TCR-抗CD3 scFv融合タンパク質の投薬レジメン
|
|
US11630103B2
(en)
|
2016-08-17 |
2023-04-18 |
The Broad Institute, Inc. |
Product and methods useful for modulating and evaluating immune responses
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
JP2020501508A
(ja)
|
2016-09-15 |
2020-01-23 |
クアドルセプト バイオ リミテッド |
多量体、四量体および八量体
|
|
US12499971B2
(en)
|
2016-09-28 |
2025-12-16 |
The Broad Institute, Inc. |
Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
|
|
US12447213B2
(en)
|
2016-10-07 |
2025-10-21 |
The Broad Institute, Inc. |
Modulation of novel immune checkpoint targets
|
|
EP4338799A3
(en)
|
2016-10-18 |
2024-06-05 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
|
GB201617714D0
(en)
|
2016-10-19 |
2016-11-30 |
Ucl Business Plc |
T Cell receptor
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
WO2018089386A1
(en)
|
2016-11-11 |
2018-05-17 |
The Broad Institute, Inc. |
Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
|
|
CN108117596B
(zh)
*
|
2016-11-29 |
2023-08-29 |
香雪生命科学技术(广东)有限公司 |
针对ny-eso的高亲和力tcr
|
|
CN110352068A
(zh)
|
2016-12-02 |
2019-10-18 |
南加利福尼亚大学 |
合成的免疫受体及其使用方法
|
|
US10583156B2
(en)
|
2016-12-02 |
2020-03-10 |
Taiga Biotechnologies, Inc. |
Nanoparticle formulations
|
|
WO2018129270A1
(en)
|
2017-01-05 |
2018-07-12 |
Fred Hutchinson Cancer Research Center |
Systems and methods to improve vaccine efficacy
|
|
AU2018205234B2
(en)
|
2017-01-06 |
2024-09-19 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (TILs) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILs and TNFRSF agonists
|
|
ES3055314T3
(en)
|
2017-01-06 |
2026-02-11 |
Iovance Biotherapeutics Inc |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
AU2018207172B2
(en)
*
|
2017-01-13 |
2023-10-12 |
Mink Therapeutics, Inc. |
T cell receptors that bind to NY-ESO-1 and methods of use thereof
|
|
EP3574116A1
(en)
|
2017-01-24 |
2019-12-04 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
|
CN110809716B
(zh)
|
2017-02-12 |
2023-07-07 |
百欧恩泰美国公司 |
基于hla的方法和组合物及其用途
|
|
BR112019018915A2
(pt)
|
2017-03-15 |
2020-04-14 |
Pandion Therapeutics Inc |
imunotolerância direcionada
|
|
CA3056837A1
(en)
|
2017-03-27 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Improved antigen binding receptors
|
|
US11963966B2
(en)
|
2017-03-31 |
2024-04-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
|
EP3606518A4
(en)
|
2017-04-01 |
2021-04-07 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
|
|
US12590288B2
(en)
|
2017-04-12 |
2026-03-31 |
The Broad Institute, Inc. |
Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response
|
|
US20200071773A1
(en)
|
2017-04-12 |
2020-03-05 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
|
US20210293783A1
(en)
|
2017-04-18 |
2021-09-23 |
The General Hospital Corporation |
Compositions for detecting secretion and methods of use
|
|
US12226479B2
(en)
|
2017-05-11 |
2025-02-18 |
The General Hospital Corporation |
Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
|
|
EP3625342B1
(en)
|
2017-05-18 |
2022-08-24 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
AU2018273914A1
(en)
|
2017-05-24 |
2019-11-14 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
|
EP3638218A4
(en)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
|
|
CN111511375A
(zh)
|
2017-06-30 |
2020-08-07 |
因提玛生物科学公司 |
用于基因治疗的腺相关病毒载体
|
|
WO2019014581A1
(en)
|
2017-07-14 |
2019-01-17 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
|
|
EP4026554A1
(en)
|
2017-08-03 |
2022-07-13 |
Taiga Biotechnologies, Inc. |
Methods and compositions for the treatment of melanoma
|
|
US10149898B2
(en)
|
2017-08-03 |
2018-12-11 |
Taiga Biotechnologies, Inc. |
Methods and compositions for the treatment of melanoma
|
|
KR102338449B1
(ko)
|
2017-09-21 |
2021-12-10 |
더 브로드 인스티튜트, 인코퍼레이티드 |
표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물
|
|
CN117843810A
(zh)
|
2017-09-22 |
2024-04-09 |
上海药明生物技术有限公司 |
新型双特异性多肽复合物
|
|
CN109535257B
(zh)
|
2017-09-22 |
2021-05-28 |
同润生物医药(上海)有限公司 |
新型双特异性cd3/cd19多肽复合物
|
|
WO2019070755A1
(en)
|
2017-10-02 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
|
|
WO2019069125A1
(en)
|
2017-10-06 |
2019-04-11 |
Oslo Universitetssykehus Hf |
CHIMERIC ANTIGEN RECEPTORS
|
|
US11732257B2
(en)
|
2017-10-23 |
2023-08-22 |
Massachusetts Institute Of Technology |
Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries
|
|
EP3700932A1
(en)
*
|
2017-10-27 |
2020-09-02 |
Kite Pharma, Inc. |
T cell receptor antigen binding molecules and methods of use thereof
|
|
US12171783B2
(en)
|
2017-11-13 |
2024-12-24 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas
|
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
|
JP2021503885A
(ja)
|
2017-11-22 |
2021-02-15 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
末梢血からの末梢血リンパ球(pbl)の拡大培養
|
|
CN109837245A
(zh)
*
|
2017-11-25 |
2019-06-04 |
深圳宾德生物技术有限公司 |
一种tcr敲除的靶向ny-eso-1的t细胞受体基因修饰t细胞及其制备方法和应用
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
EP3724885A2
(en)
|
2017-12-15 |
2020-10-21 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
|
WO2019143948A1
(en)
|
2018-01-18 |
2019-07-25 |
Fred Hutchinson Cancer Research Center |
Altering inflammatory states of immune cells in vivo by modulating cellular activation states
|
|
US11267864B2
(en)
*
|
2018-02-26 |
2022-03-08 |
Medigene Immunotherapies Gmbh |
Nyeso tcr
|
|
JP7412006B2
(ja)
|
2018-03-14 |
2024-01-12 |
メディジーン イミュノテラピーズ ゲーエムベーハー |
誘導性t細胞レセプター及びその使用
|
|
EP3773633A4
(en)
|
2018-04-06 |
2022-01-26 |
The Regents of The University of California |
METHODS OF TREATMENT OF GLIOBLASTOMA
|
|
CA3096202A1
(en)
|
2018-04-06 |
2019-10-10 |
The Regents Of The University Of California |
Methods of treating egfrviii expressing glioblastomas
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
WO2020033923A1
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antigen binding agents that bind cd277 and uses thereof
|
|
US12391685B2
(en)
|
2018-08-20 |
2025-08-19 |
The Broad Institute, Inc. |
Inhibitors of RNA-guided nuclease target binding and uses thereof
|
|
WO2020041384A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
|
|
WO2020041387A1
(en)
|
2018-08-20 |
2020-02-27 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
|
US20210317184A1
(en)
|
2018-09-05 |
2021-10-14 |
GlaxoSmithKline Intellectual Property Devolopment Limited |
T cell modification
|
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
|
CN113454110B
(zh)
|
2018-10-23 |
2024-07-02 |
里珍纳龙药品有限公司 |
Ny-eso-1 t细胞受体和其使用方法
|
|
WO2020092455A2
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
|
US12466892B2
(en)
|
2018-11-08 |
2025-11-11 |
The Regents Of The University Of California |
Systems and methods for targeting cancer cells
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
CA3124457A1
(en)
|
2018-12-21 |
2020-06-25 |
Biontech Us Inc. |
Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
SG11202109331QA
(en)
|
2019-03-01 |
2021-09-29 |
Iovance Biotherapeutics Inc |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
WO2020182681A1
(en)
|
2019-03-08 |
2020-09-17 |
Klinikum Der Universität München |
Ccr8 expressing lymphocytes for targeted tumor therapy
|
|
WO2020186101A1
(en)
|
2019-03-12 |
2020-09-17 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
US12473346B2
(en)
|
2019-03-18 |
2025-11-18 |
Ludwig Institute For Cancer Research Ltd |
A2/NY-ESO-1 specific t cell receptors and uses thereof
|
|
GB201903767D0
(en)
|
2019-03-19 |
2019-05-01 |
Quadrucept Bio Ltd |
Multimers, tetramers & octamers
|
|
GB201904328D0
(en)
*
|
2019-03-28 |
2019-05-15 |
Immunocore Ltd |
Specific binding molecules
|
|
EP3952909A4
(en)
|
2019-04-08 |
2023-06-07 |
Taiga Biotechnologies, Inc. |
COMPOSITIONS AND METHODS FOR CRYOPRESERVING IMMUNE CELLS
|
|
SG11202112529WA
(en)
|
2019-05-14 |
2021-12-30 |
Taiga Biotechnologies Inc |
Compositions and methods for treating t cell exhaustion
|
|
AU2020279240A1
(en)
|
2019-05-20 |
2021-12-23 |
Pandion Operations, Inc. |
MAdCAM targeted immunotolerance
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
|
CN114245807B
(zh)
|
2019-06-25 |
2025-05-02 |
吉利德科学公司 |
Flt3l-fc融合蛋白和使用方法
|
|
JP7674278B2
(ja)
*
|
2019-07-03 |
2025-05-09 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗ニューヨーク食道扁平上皮がん1(ny-eso-1)抗原結合タンパク質およびその使用方法
|
|
CN112300268B
(zh)
*
|
2019-08-02 |
2023-02-28 |
香雪生命科学技术(广东)有限公司 |
识别ny-eso-1抗原的高亲和力t细胞受体
|
|
WO2021030182A1
(en)
|
2019-08-09 |
2021-02-18 |
A2 Biotherapeutics, Inc. |
Bifunctional single variable domain t cell receptors and uses thereof
|
|
US20220282333A1
(en)
|
2019-08-13 |
2022-09-08 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
CN114555791B
(zh)
|
2019-08-13 |
2026-07-14 |
伦敦国王学院 |
Il-1超家族时空限制性活性细胞因子铠装的免疫应答细胞
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
|
US12195723B2
(en)
|
2019-11-08 |
2025-01-14 |
The Broad Institute, Inc. |
Engineered antigen presenting cells and uses thereof
|
|
US11865168B2
(en)
|
2019-12-30 |
2024-01-09 |
Massachusetts Institute Of Technology |
Compositions and methods for treating bacterial infections
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
TWI890283B
(zh)
|
2020-02-14 |
2025-07-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|
|
WO2021190980A1
(en)
|
2020-03-22 |
2021-09-30 |
Quadrucept Bio Limited |
Multimers for viral strain evolution
|
|
CA3175577A1
(en)
|
2020-03-30 |
2021-10-07 |
Mie University |
Bispecific antibody
|
|
CN111690051B
(zh)
*
|
2020-06-28 |
2021-08-17 |
英威福赛生物技术有限公司 |
靶向ny-eso-1(157-165)表位的特异性t细胞受体及抗肿瘤应用
|
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
KR20230112632A
(ko)
|
2020-10-23 |
2023-07-27 |
애셔 바이오테라퓨틱스, 인크. |
면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
|
|
US20250082680A1
(en)
|
2021-02-09 |
2025-03-13 |
Liyang Tcr Biotherapeutics Co. Ltd |
Tcr and application thereof
|
|
TW202246511A
(zh)
|
2021-02-25 |
2022-12-01 |
美商萊爾免疫藥物股份有限公司 |
靶向ny-eso-1之增強免疫細胞療法
|
|
US20240150711A1
(en)
|
2021-03-01 |
2024-05-09 |
Dana-Farber Cancer Institute, Inc. |
Personalized redirection and reprogramming of t cells for precise targeting of tumors
|
|
WO2022184659A1
(en)
|
2021-03-01 |
2022-09-09 |
Quadrucept Bio Limited |
Antibody domains & multimers
|
|
WO2022245671A1
(en)
|
2021-05-18 |
2022-11-24 |
Gilead Sciences, Inc. |
Methods of using flt3l-fc fusion proteins
|
|
EP4370541A1
(en)
|
2021-07-14 |
2024-05-22 |
2seventy bio, Inc. |
Engineered t cell receptors fused to binding domains from antibodies
|
|
WO2023021113A1
(en)
|
2021-08-18 |
2023-02-23 |
Julius-Maximilians-Universität Würzburg |
Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
|
|
EP4423078A1
(en)
|
2021-10-28 |
2024-09-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
WO2023077028A1
(en)
|
2021-10-28 |
2023-05-04 |
Lyell Immunopharma, Inc. |
Enhanced t cell therapy targeting ny-eso-1
|
|
PE20241186A1
(es)
|
2021-10-29 |
2024-06-03 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
CN118488948A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
|
US20240124412A1
(en)
|
2021-12-22 |
2024-04-18 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CA3248911A1
(en)
|
2022-01-28 |
2023-08-03 |
Gilead Sciences, Inc. |
POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
|
|
US12103971B2
(en)
|
2022-02-20 |
2024-10-01 |
Immunocore Limited |
HIV specific binding molecules
|
|
PL4245756T3
(pl)
|
2022-03-17 |
2025-02-17 |
Gilead Sciences, Inc. |
Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
|
|
AU2023248532A1
(en)
|
2022-04-08 |
2024-11-21 |
Regeneron Pharmaceuticals, Inc. |
Multipartite receptor and signaling complexes
|
|
EP4511127A1
(en)
|
2022-04-21 |
2025-02-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
EP4519305A4
(en)
*
|
2022-05-02 |
2026-05-06 |
Tscan Therapeutics Inc |
Compositions of multiplexed T-lymphocyte receptors, polytherapies and their uses
|
|
WO2024006929A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
EP4598949A1
(en)
|
2022-10-07 |
2025-08-13 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
|
|
US20260124242A1
(en)
|
2022-11-04 |
2026-05-07 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
US20260201034A1
(en)
*
|
2022-12-05 |
2026-07-16 |
Board Of Regents, The University Of Texas System |
A t cell receptor recognizing a her2 mutation presented on hla-a*02:01 and methods of use
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
CN116239700B
(zh)
*
|
2022-12-20 |
2024-06-21 |
浙江大学 |
一种肿瘤双靶向的三特异性t细胞衔接器及其应用
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
CN116284448B
(zh)
*
|
2023-02-14 |
2024-06-21 |
浙江大学 |
一种超抗原参与的三功能t细胞衔接器及其应用
|
|
WO2024192141A1
(en)
|
2023-03-13 |
2024-09-19 |
Dana-Farber Cancer Institute, Inc. |
Treatment of cancers having a drug-resistant mesenchymal cell state
|
|
WO2024215754A1
(en)
|
2023-04-11 |
2024-10-17 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
PE20260121A1
(es)
|
2023-04-21 |
2026-01-16 |
Gilead Sciences Inc |
Inhibidores de prmt5 y usos de los mismos
|
|
WO2024226838A2
(en)
|
2023-04-25 |
2024-10-31 |
The Brigham And Women's Hospital, Inc. |
Treatment of autoimmune diseases having a pathogenic t cell state
|
|
JP2026522894A
(ja)
|
2023-06-30 |
2026-07-09 |
ギリアード サイエンシーズ, インコーポレイテッド |
Kras調節化合物
|
|
AU2024297978A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
CN121568935A
(zh)
|
2023-07-26 |
2026-02-24 |
吉利德科学公司 |
Parp7抑制剂
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
EP4774280A1
(en)
|
2023-09-08 |
2026-07-15 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025096589A1
(en)
|
2023-11-03 |
2025-05-08 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
US20250230168A1
(en)
|
2023-12-22 |
2025-07-17 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20260098049A1
(en)
|
2024-08-12 |
2026-04-09 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
US20260130893A1
(en)
|
2024-10-21 |
2026-05-14 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026136515A1
(en)
|
2024-12-19 |
2026-06-25 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|